Get the Stockscreener App
292.60
3.51%
-10.63
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cencora Inc stock is traded at $292.60, with a volume of 1.63M.
It is down -3.51% in the last 24 hours and down -0.13% over the past month.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
See More
Previous Close:
$303.23
Open:
$304.59
24h Volume:
1.63M
Relative Volume:
1.30
Market Cap:
$56.73B
Revenue:
$316.65B
Net Income/Loss:
$1.91B
P/E Ratio:
30.10
EPS:
9.72
Net Cash Flow:
$1.14B
1W Performance:
-0.08%
1M Performance:
-0.13%
6M Performance:
+21.19%
1Y Performance:
+21.62%
1-Day Range:
$291.48
$305.27
1-Week Range:
$288.32
$306.28
52-Week Range:
$218.65
$309.35
Cencora Inc Stock (COR) Company Profile
Name
Cencora Inc
Sector
Industry
Phone
610-727-7000
Address
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
292.60 | 56.29B | 316.65B | 1.91B | 1.14B | 9.72 |
|
MCK
Mckesson Corporation
|
689.45 | 83.49B | 377.60B | 3.35B | 5.67B | 25.08 |
|
CAH
Cardinal Health Inc
|
148.10 | 35.75B | 222.58B | 1.57B | 1.85B | 6.45 |
|
HSIC
Henry Schein Inc
|
69.60 | 8.15B | 12.50B | 314.00M | 421.00M | 2.44 |
|
AHG
Akso Health Group Adr
|
1.77 | 701.93M | 2.22M | -5.63M | -1.68M | -0.24 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Sep-18-24 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Jan-31-23 | Resumed | Evercore ISI | Outperform |
| Oct-11-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-11-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| May-26-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-12-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Resumed | Evercore ISI | In-line |
| Feb-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-02-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-06-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-10-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Dec-03-20 | Initiated | Mizuho | Neutral |
| Aug-06-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-15-20 | Initiated | Barclays | Underweight |
| Jun-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-23-20 | Resumed | Credit Suisse | Outperform |
| Apr-16-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-13-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-01-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-20 | Downgrade | BofA/Merrill | Buy → Underperform |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Jul-10-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-11-19 | Initiated | Guggenheim | Buy |
| Apr-10-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Apr-10-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-10-18 | Downgrade | Jefferies | Buy → Hold |
| Oct-26-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-20-18 | Initiated | Berenberg | Buy |
| Jul-17-18 | Resumed | Stifel | Hold |
| Apr-09-18 | Initiated | MoffettNathanson | Buy |
| Mar-12-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Mar-12-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-25-17 | Initiated | JP Morgan | Neutral |
| Sep-22-17 | Initiated | William Blair | Outperform |
View All
Cencora Inc Stock (COR) Latest News
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Published on: 2025-08-21 02:56:19 - classian.co.kr
Cencora directors ink $111M deal related to opioid claims - MSN
Cencora Inc. Rebound Backed by Sentiment ShiftWeekly Market Report & Safe Investment Capital Preservation Plans - kangso.co.kr
Cencora Posts Modest 1.5 Gain as Volume Plunge Sends Stock to 405th Trading Rank Amid Sector Restructuring Focus - AInvest
What makes Cencora Inc. stock price move sharplyJuly 2025 Reactions & Verified Entry Point Signals - newsyoung.net
Cencora directors settle opioid claims for $111M - AInvest
Cencora directors ink $111M opioid deal (COR:NYSE) - Seeking Alpha
Cencora Shares Dip 0.70% as $320M Volume Ranks 332nd Amid Strategic Shifts and Sector Volatility - AInvest
$111.25M Del. Settlement Proposed For Cencora Opioid Suits - Law360
Cencora Directors Settle Opioid Claims for $111 Million - AInvest
Cencora Directors Reach $111 Million Deal on Opioid Claims - Bloomberg.com
Why Cencora (COR) is a Top Value Stock for the Long-Term - Yahoo Finance
Cencora’s 1.32% Rally Amid 295th-Ranked $350M Volume as Industry Navigates Regulatory Shifts and Profit Volatility - AInvest
Cencora Inc. Tests 50 Day MA After Sharp DeclineWeekly Stock Analysis & Stock Portfolio Risk Control - newsyoung.net
Will Cencora Inc. stock go up in YEARMarket Performance Report & Community Verified Watchlist Alerts - newsimpact.co.kr
Short Term Trend Reversal in Cencora Inc. PossibleJuly 2025 Catalysts & High Accuracy Buy Signal Tips - thegnnews.com
Cencora (COR) Stock Surpasses Market Gains with Strong PerformanceNews and Statistics - IndexBox
Ex-Dividend Reminder: Cencora, Organon and Esquire Financial Holdings - Nasdaq
Cencora Stock: Analyst Estimates & Ratings - Yahoo Finance
Wells Fargo raises Cencora stock price target to $354 on strong U.S. Healthcare performance - Investing.com
Cencora price target raised to $354 from $337 at Wells Fargo - TipRanks
Stock Analysis | Cencora OutlookMixed Signals as Technicals and Analysts Diverge - AInvest
Cencora Plummets 0.53% Amid Regulatory Scrutiny Ranks 189th in $580M Trading Volume Despite Sector Resilience - AInvest
Investors Still Waiting For A Pull Back In Cencora, Inc. (NYSE:COR) - 富途牛牛
Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap (NYSE:COR) - Seeking Alpha
Cencora (COR) Plummets 2.44% Amid Volatile Intraday Move: What’s Fueling the Selloff? - AInvest
Cencora Lifts Earnings Outlook After Strong Q3 Performance - MSN
Cencora & The Lash Group Settle Data Breach Litigation for $40 Million - The HIPAA Journal
Cencora (COR) Shares Jump 1.95% as Trading Volume Surges to $530M Ranking 184th in Market Activity - AInvest
3 Reasons Growth Investors Will Love Cencora (COR) - Yahoo Finance
RSI Suggests Rebound May Be Near in Cencora Inc.Top Gaining Picks With Entry Signals Identified - beatles.ru
Is It Smart To Buy Cencora, Inc. (NYSE:COR) Before It Goes Ex-Dividend? - simplywall.st
Why You Might Be Interested In Cencora, Inc. (NYSE:COR) For Its Upcoming Dividend - ca.finance.yahoo.com
Published on: 2025-08-10 00:34:30 - metal.it
Cencora, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
Cencora Rises 2.42% as Trading Volume Slumps to 313th Market Rank - AInvest
Cencora Q3: Growing Specialty Drug Distributions; Initiate At Buy (NYSE:COR) - Seeking Alpha
Research Alert: CFRA Raises View On Shares Of Cencora, Inc. To Buy From Hold - 富途牛牛
Can Specialty and GLP-1 Momentum Support Cencora's Q3 Results? - MSN
Cencora, Inc. Reports Strong Q3 2025 Financial Results - The Globe and Mail
Cencora Reports Strong Q3 2025 Financial Results - The Globe and Mail
Cencora: Fiscal Q3 Earnings Snapshot - New Haven Register
Cencora (COR) Reports Q3 Earnings Growth, Maintains US$0.55 Dividend - simplywall.st
Cencora’s Earnings Call: Strong Growth Amid Challenges - TipRanks
Cencora Earnings: Solid Results Illustrate Healthy Demand and Stable Outlook; Shares Fairly Valued - Morningstar
Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook - AOL.com
Cencora Benefits From Strong GLP-1 Sales, Healthy Utilization Trends, and Growing Specialty Assets - Morningstar
Cencora, Inc. SEC 10-Q Report - TradingView
Cencora raises 2025 EPS guidance to $15.85–$16 and narrows outlook as specialty drives growth - MSN
Cencora weakness after earnings ‘overdone,’ says Leerink - TipRanks
Cencora Inc Stock (COR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.29%
2.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):